MA30063B1 - Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg) - Google Patents

Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)

Info

Publication number
MA30063B1
MA30063B1 MA31047A MA31047A MA30063B1 MA 30063 B1 MA30063 B1 MA 30063B1 MA 31047 A MA31047 A MA 31047A MA 31047 A MA31047 A MA 31047A MA 30063 B1 MA30063 B1 MA 30063B1
Authority
MA
Morocco
Prior art keywords
aryluree
fcg
pyrimidinyl
inhibitors
derivatives
Prior art date
Application number
MA31047A
Other languages
English (en)
Inventor
Guido Bold
Pascal Furet
Vito Guagnano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30063B1 publication Critical patent/MA30063B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des hétéroarylarylurées de formule IA : dans laquelle les radicaux et les symboles ont les significations définies ici, l'utilisation de ces composés dans le traitement de maladies sous la dépendance de protéine-kinases, des préparations pharmaceutiques comprenant lesdites hétéroarylarylurées, des procédés de fabrication de ces nouveaux composés et des procédés de traitement comprenant l'utilisation de ces hétéroarylarylurées.
MA31047A 2005-12-21 2008-06-18 Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg) MA30063B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75271105P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
MA30063B1 true MA30063B1 (fr) 2008-12-01

Family

ID=37946774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31047A MA30063B1 (fr) 2005-12-21 2008-06-18 Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)

Country Status (22)

Country Link
US (2) US8293746B2 (fr)
EP (1) EP1976847B1 (fr)
JP (1) JP5153645B2 (fr)
KR (1) KR101406956B1 (fr)
CN (1) CN101336237B (fr)
AU (1) AU2006326989B2 (fr)
BR (1) BRPI0620408B8 (fr)
CA (1) CA2634047C (fr)
CR (1) CR10072A (fr)
EA (1) EA016438B1 (fr)
EC (1) ECSP088561A (fr)
GE (1) GEP20105074B (fr)
HN (1) HN2008000949A (fr)
IL (1) IL192093A0 (fr)
MA (1) MA30063B1 (fr)
ME (2) ME00011A (fr)
NO (1) NO20083214L (fr)
SM (1) SMP200800041B (fr)
SV (1) SV2008002967A (fr)
TN (1) TNSN08276A1 (fr)
WO (1) WO2007071752A2 (fr)
ZA (1) ZA200805092B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2007071752A2 (fr) * 2005-12-21 2007-06-28 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
JP2013503193A (ja) * 2009-08-28 2013-01-31 ジェネンテック， インコーポレイテッド Ｒａｆ阻害剤化合物およびその使用方法
ES2524548T3 (es) * 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
JP2013514986A (ja) * 2009-12-18 2013-05-02 ノバルティス アーゲー 血液癌の処置方法
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
EP2821402B1 (fr) 2012-02-28 2019-08-21 Astellas Pharma Inc. Composé hétérocyclique aromatique contenant de l'azote
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MX2015002959A (es) * 2013-03-10 2015-06-05 Univ Nagoya Nat Univ Corp Agente terapeutico para padecimiento sistemico oseo y uso del mismo.
JP2016515508A (ja) 2013-03-15 2016-05-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 融合タンパク質及びその方法
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
NZ711376A (en) 2013-03-15 2020-01-31 Sanofi Sa Heteroaryl compounds and uses thereof
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
EP2789619A1 (fr) 2013-04-12 2014-10-15 Kemotech S.r.l. Composés pharmaceutiques ayant une activité inhibitrice de l'angiogenèse
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
CA2917667A1 (fr) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase pour le traitement d'une maladie
AU2014337291B9 (en) * 2013-10-18 2020-05-07 Eisai R&D Management Co., Ltd. Pyrimidine FGFR4 inhibitors
ES2682493T3 (es) 2013-10-25 2018-09-20 Novartis Ag Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de FGFR4
EP3079667B1 (fr) 2013-12-13 2019-06-26 Novartis AG Formes pharmaceutiques
EP3171874B1 (fr) 2014-07-21 2020-11-18 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'imidazolyl kinase et leurs utilisations
DK3172213T3 (da) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
EP3536323A1 (fr) * 2014-08-08 2019-09-11 Dana Farber Cancer Institute, Inc. Utilisations d'inhibiteurs de kinases inductibles par un sel (sik)
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
US20180185341A1 (en) * 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3237452A4 (fr) 2014-12-23 2018-12-05 The Trustees of Columbia University in the City of New York Protéines de fusion et procédés associés
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
MX2017013248A (es) 2015-04-14 2018-07-06 Eisai R&D Man Co Ltd Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
US10624897B2 (en) 2015-07-20 2020-04-21 Taipei Medical University Chlorobenzene substituted azaaryl compounds
WO2017118438A1 (fr) * 2016-01-08 2017-07-13 杭州英创医药科技有限公司 Composé hétérocyclique utilisé en tant qu'inhibiteur de fgfr
EP3454898B1 (fr) 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Associations médicamenteuses permettant de réduire la viabilité et/ou la prolifération cellulaire
CN110225914A (zh) 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
WO2018053373A1 (fr) 2016-09-16 2018-03-22 The General Hospital Corporation Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose
DK3555070T3 (da) * 2016-12-19 2023-09-18 Epizyme Inc Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
JP7296318B2 (ja) 2017-02-28 2023-06-22 ザ ジェネラル ホスピタル コーポレイション Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019189241A1 (fr) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour le carcinome hépatocellulaire
WO2019213544A2 (fr) 2018-05-04 2019-11-07 Incyte Corporation Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
CN109053593B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053594B (zh) * 2018-08-07 2020-12-18 温州医科大学 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053592B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
CN110283130B (zh) * 2019-07-05 2023-12-19 温州医科大学 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CA3162010A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Derives d'un inhibiteur de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759921A (en) * 1969-10-16 1973-09-18 Lilly Co Eli Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
ES2282299T3 (es) * 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ITMI20010528A1 (it) 2001-03-13 2002-09-13 Istituto Biochimico Pavese Pha Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche
US20020156257A1 (en) 2001-03-29 2002-10-24 Chunhua Yan Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2003101444A1 (fr) 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
AU2003299750A1 (en) 2002-12-20 2004-07-22 Irm Llc Differential tumor cytotoxocity compounds and compositions
WO2005030735A1 (fr) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Derives de triazines comme inhibiteurs de l'adhesion cellulaire
TW200529849A (en) 2003-11-28 2005-09-16 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
US20070293484A1 (en) 2004-05-20 2007-12-20 Sugen, Inc. Thiophene Heteroaryl Amines
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (fr) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese
CA2586870A1 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes modulateurs de la il-12
EP1928843A1 (fr) * 2005-08-22 2008-06-11 Amgen, Inc Composes d'uree de bis-aryle pour le traitement de maladies mediees par une proteine kinase
WO2007071752A2 (fr) * 2005-12-21 2007-06-28 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
US20090062320A1 (en) * 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor

Also Published As

Publication number Publication date
GEP20105074B (en) 2010-09-10
US20080312248A1 (en) 2008-12-18
US8293746B2 (en) 2012-10-23
EP1976847A2 (fr) 2008-10-08
WO2007071752A2 (fr) 2007-06-28
CA2634047C (fr) 2016-04-12
EA016438B1 (ru) 2012-05-30
CN101336237A (zh) 2008-12-31
SMAP200800041A (it) 2008-07-23
US8759517B2 (en) 2014-06-24
AU2006326989B2 (en) 2011-11-24
HN2008000949A (es) 2010-11-11
KR20080090439A (ko) 2008-10-08
TNSN08276A1 (en) 2009-10-30
ME00011A (fr) 2009-02-10
JP5153645B2 (ja) 2013-02-27
IL192093A0 (en) 2008-12-29
KR101406956B1 (ko) 2014-06-13
US20130030171A1 (en) 2013-01-31
BRPI0620408A2 (pt) 2011-11-08
EP1976847B1 (fr) 2015-06-17
ECSP088561A (es) 2008-07-30
CN101336237B (zh) 2015-09-30
NO20083214L (no) 2008-09-01
AU2006326989A1 (en) 2007-06-28
CA2634047A1 (fr) 2007-06-28
BRPI0620408B8 (pt) 2021-05-25
CR10072A (es) 2008-08-25
EA200801565A1 (ru) 2008-12-30
JP2009520768A (ja) 2009-05-28
MEP3808A (xx) 2010-02-10
BRPI0620408B1 (pt) 2020-09-15
SMP200800041B (it) 2009-07-14
ZA200805092B (en) 2009-09-30
SV2008002967A (es) 2011-01-24
WO2007071752A3 (fr) 2007-11-08

Similar Documents

Publication Publication Date Title
MA30063B1 (fr) Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
MA31090B1 (fr) Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
BRPI0515489A (pt) derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
HRP20060251A2 (en) Substituted oxasolidinones and their use
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
MEP20908A (en) Thienopyrazoles
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
SE0104331D0 (sv) Novel compounds
HRP20041048B1 (hr) POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen